Clinical Trials Logo

Peritoneal Cancer clinical trials

View clinical trials related to Peritoneal Cancer.

Filter by:

NCT ID: NCT02741167 Recruiting - Peritoneal Cancer Clinical Trials

Pathophysiology of Inflammation After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

Start date: January 2016
Phase: N/A
Study type: Observational

The purpose of this study is to assess the dynamics of inflammatory parameters in presence or absence of infectious complications after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.

NCT ID: NCT02534922 Recruiting - Ovarian Cancer Clinical Trials

Study of Prolanta™ in Recurrent or Persistent Epithelial Ovarian Cancer

ProlantaOC
Start date: February 2016
Phase: Phase 1
Study type: Interventional

This trial is a Phase I open-label safety study of Prolanta™, a recombinant analog of the human prolactin protein with a single amino acid substitution to create an antagonist of the prolactin receptor. The Sponsor believes that blocking the prolactin receptor in patients with ovarian and other cancers will be effective as a monotherapy or in combination with other chemotherapies. This Phase I study will be conducted in Subjects with recurrent or persistent epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.

NCT ID: NCT02433626 Recruiting - Colorectal Cancer Clinical Trials

Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies

COTI2-101
Start date: December 2015
Phase: Phase 1
Study type: Interventional

Activity of COTI-2 has been demonstrated in various cancer tumor models. With its p53- and AKT-based mechanisms of action, COTI-2 is anticipated to be highly relevant in treatment of patients with gynecologic malignancies or head and neck squamous cell carcinoma (HNSCC) as well as a variety of other tumor types. This study is designed primarily to assess the safety and tolerability of COTI-2 monotherapy or combination therapy in patients with advanced and recurrent malignancies to establish a recommended Phase 2 dose (RP2D) for future studies. Patients are currently being recruited for Part 3 of the study. Critical Outcome Technologies Inc. has been renamed to Cotinga Pharmaceuticals.

NCT ID: NCT02349958 Recruiting - Ovarian Cancer Clinical Trials

Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy

HIPEC/IPHC
Start date: September 2006
Phase: Phase 2
Study type: Interventional

To determine treatment response to surgical debulking and intra-operative Intraperitoneal Hyperthermic Chemotherapy (IPHC) in patients with the following malignancies: Gynecologic cancers (ovarian, primary peritoneal or fallopian tube, and uterine/cervical cancers). Mesotheliomas. GI cancers (Gallbladder, liver, small intestine, pancreas, stomach, colon, appendix). To monitor the toxicities and complications of this treatment regimen. To measure treatment related QOL changes after IPHC.